However, a meta-analysis including 4 studies showed no increased VTE risk in patients with homozygous 4G/4G PAI-1 mutations in patients with cancer (OR 1.46, 95% CI: 0.65–3.29; Table 1), strongly arguing against an important role for PAI-1 mutation as a germline predictor in this population [17▪]. This evidence concerns the gene SERPINE1 and cancer.